Skip to main content
. 2017 Dec 18;97(3):497–507. doi: 10.1007/s00277-017-3204-6

Table 1.

Patient characteristics

CR group Advanced group P value
No. patients 32 31
Median age, years (range) 37 (15–52) 41 (19–62) P = 0.24
Sex P = 0.32
 Male 18 13
 Female 14 18
Diagnosis P = 0.479
 De novo AML 31 28
 Secondary AML 1 2
 MDS-AML 0 1
Risk classification at diagnosis* P = 0.001
 High 11 24
 Intermediate 21 7
Median interval from diagnosis to HSCT, months (range) 8 (3–19) 8 (3–68) P = 0.096
Tapering of immunosuppressive agents
 Early 7 22 P < 0.001
 Regular 25 9
Disease status at transplantation
 CR1 25
 CR2 7
 Secondary refractory 23
 Primary refractory 8
Donor characteristics P = 0.556
 Matched related (10/10) 15 14
 Matched unrelated (10/10) 10 12
 Matched unrelated (9/10) 7 5
Conditioning regimens P = 0.359
 BFAT 18 15
 BCAT 14 16

CR complete remission, AML acute myeloid leukemia, MDS-AML myelodysplastic syndrome-related acute myeloid leukemia, BFAT busulfan+fludarabine+Ara-C+TBI, BCAT busulfan+cladribine+Ara-C+TBI

*Risk classification at diagnosis was evaluated according to the cytogenetics at the time of diagnosis [21]